Effect of Quercetin on Prophylaxis and Treatment of COVID-19
The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19
1 other identifier
interventional
447
1 country
1
Brief Summary
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. The investigators hypothesize that quercetin, as a strong scavenger and anti-inflammatory agent, can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, the aim of this study to evaluate the possible role of quercetin on prophylaxis and treatment of COVID-19.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable covid19
Started Mar 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 20, 2020
CompletedFirst Submitted
Initial submission to the registry
May 1, 2020
CompletedFirst Posted
Study publicly available on registry
May 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2020
CompletedFebruary 18, 2021
February 1, 2021
4 months
May 1, 2020
February 17, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Prevalence of COVID-19 calculated using a questionnaire
Prevalence of COVID-19 in prophylaxis and sham group will be calculated using a questionnaire including hospital records
3 months
Standardized Mortality rate
Mortality rate will be compared between two groups
3 months
Secondary Outcomes (1)
Morbidity rate
3 months
Study Arms (3)
non-quercetin group
NO INTERVENTIONParticipants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
quercetin prophylaxis group
ACTIVE COMPARATORParticipants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
quercetin treatment group
ACTIVE COMPARATORParticipants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
Interventions
a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
Eligibility Criteria
You may qualify if:
- moderate-high risk for COVID-19
- obtained informed consent
You may not qualify if:
- declined to participate
- genetic/chromosomal abnormalities
- any kind of sensitivity or allergy for quercetin
- history of previous hypersensitivity with quercetin
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, 34303, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 1, 2020
First Posted
May 6, 2020
Study Start
March 20, 2020
Primary Completion
July 31, 2020
Study Completion
August 31, 2020
Last Updated
February 18, 2021
Record last verified: 2021-02